Founded to find a cure for a daughter’s rare disease, United Therapeutics is a biotechnology company transforming care for people with chronic and life-threatening conditions. Our purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. We are bold and unconventional. We have fun, we do good. We are also the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation. 

In July 2026, United Therapeutics Corporation acquired Thymmune Therapeutics, a biotechnology company based in Cambridge, Massachusetts, that develops machine learning-driven, induced pluripotent stem cell (iPSC)-derived thymic cell therapies.